An NEI peer-review panel decided that measuring how quickly vision recovers after bright light exposure is clinically meaningful enough to fund, and that judgment matters as much as the grant itself. PerZeption, a Boston-based startup, received a Phase I SBIR award from the National Eye Institute to develop a new photostress recovery test for age-related macular degeneration on its Angular Indication Measurement (AIM) tablet platform, in collaboration with the Brunson Center for Translational Vision Research at UC Irvine. Phase I NEI SBIR awards carry up to $323,090 in total costs, so the dollars are modest. The scientific endorsement is not.
The clinical problem the grant targets is specific: roughly 19.8 million Americans aged 40 and older live with some stage of AMD, and current photostress recovery testing collapses the entire recovery process into a single time point, requires dedicated equipment, and demands trained staff. That combination keeps the test out of routine practice. PerZeption’s funded work will characterize the full recovery curve, both achromatic and chromatic, on hardware clinics already own. A richer recovery profile could flag functional loss before standard acuity testing picks it up, which is where the diagnostic value sits for a disease that destroys central vision gradually.
The AIM platform already covers more than 20 visual functions and runs as a cloud application on standard tablets and phones. PerZeption says AMD photostress recovery is among the functions currently without a commercial device, and the Phase I work is explicitly framed as generating feasibility data to support a regulatory pathway. That framing signals the company intends a cleared device, not just a research instrument. The collaboration with UC Irvine gives the feasibility study academic clinical access, and the company’s prior AIM validation work has appeared in Investigative Ophthalmology & Visual Science, Optometry and Vision Science, and, published earlier this month, Scientific Reports.
The number to watch from here is what the Phase I data show about test-retest repeatability. A fast, tablet-based photostress recovery measure only displaces legacy methods in clinical workflows if its coefficient of variation is tight enough to detect disease progression reliably, and that threshold will determine whether the company’s regulatory submission holds up.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
